# Heidelberg Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/heidelberg-pharma

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.heidelberg-pharma.com
- Total disclosed funding: $20M
- Latest round: Series B (Oct 2, 2006)
- Investors on record: 1

## About

Based in Ladenburg Deutschland, Germany, and founded in 1997, Heidelberg Pharma AG formerly known as Wilex Biotechnology GmbH operates as a biotechnology that develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate. In October 2006, Heidelberg Pharma AG raised EUR 16 million in series B funding led by HDP Beteiligungs GmbH.

The company develops Antibody Drug Conjugates (ADCs) for the treatment of oncological diseases. The technology used by the firm uses Amanitin. The firm has various products which are in the research phase named HDP-104, and HDP- XX having indication gastrointestinal and solid and hematological tumors respectively.

## Funding rounds

- Series B, Oct 2, 2006, $20M — Dievini

## Investors

- Dievini (https://capitalatlas.ai/funds/dievini) — Series B